Compare ATYR & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATYR | SACH |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.2M | 47.5M |
| IPO Year | 2015 | 2017 |
| Metric | ATYR | SACH |
|---|---|---|
| Price | $0.72 | $1.07 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $8.75 | $2.00 |
| AVG Volume (30 Days) | ★ 2.1M | 274.2K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 19.42% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $190,000.00 | ★ $3,906,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18,728.88 | $1.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.64 | $0.80 |
| 52 Week High | $7.29 | $1.40 |
| Indicator | ATYR | SACH |
|---|---|---|
| Relative Strength Index (RSI) | 41.09 | 50.88 |
| Support Level | $0.70 | $0.99 |
| Resistance Level | $0.75 | $1.05 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 21.52 | 28.23 |
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.